Vesicor Therapeutics Holdings, Inc. filed a Form 8-A on November 19, 2026, to register its Class A Common Stock on the Nasdaq Capital Market in connection with its anticipated listing on November 23, 2026.
Key Highlights
- New listing: Class A Common Stock, $0.0001 par value per share, approved for listing on the Nasdaq Capital Market under the ticker symbol "VESI."
- Listing date: According to the filing, trading is scheduled to begin at the opening on November 23, 2026.
- Prior name: The registrant was formerly known as Black Hawk Acquisition Corporation, the filing disclosed.
- Incorporated in Delaware: The company is a Delaware corporation with principal offices at 207 South Santa Anita Street, Suite P-15, San Gabriel, California 91776.
- Related registration: The filing references a Form S-4 registration statement (File No. 333-292402), originally filed with the SEC on December 23, 2025, as the source for the description of the securities being registered.
- Signed by CEO: The registration statement was signed by Michael Tolentino, Chief Executive Officer, dated November 19, 2026.
Vesicor Therapeutics Registers Class A Common Stock Ahead of Nasdaq Debut
Vesicor Therapeutics Holdings, Inc. filed this Form 8-A with the U.S. Securities and Exchange Commission to register its Class A Common Stock pursuant to Section 12(b) of the Securities Exchange Act of 1934. According to the filing, the registration is being made "in connection with the listing of the Registrant's Class A common stock, $0.0001 par value per share" on The Nasdaq Stock Market LLC, with the listing scheduled for the opening of trading on November 23, 2026, under the symbol "VESI" on the Nasdaq Capital Market.
The filing identifies the company as formerly known as Black Hawk Acquisition Corporation and notes its current legal name as Vesicor Therapeutics Holdings, Inc. The registrant carries an IRS Employer Identification Number of 43-3049099 and is classified under Primary Standard Industrial Classification Code 2834. Its principal offices are located at 207 South Santa Anita Street, Suite P-15, San Gabriel, California 91776.
For the description of the securities being registered, the filing states that the registrant incorporates by reference the section titled "Description of PubCo Securities" contained in its Form S-4 registration statement (File No. 333-292402), originally filed on December 23, 2025, and subsequently amended. No exhibits were filed with this Form 8-A, as the filing noted that none are required under the applicable instructions given the circumstances of the registration.
What Was Disclosed
Vesicor Therapeutics Holdings, Inc. registered its Class A Common Stock, $0.0001 par value per share, for listing on NASDAQ:VESI via a Form 8-A filed November 19, 2026, with trading scheduled to commence November 23, 2026.





Please wait processing your request...